News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theraclone Sciences, Inc. Announces Pfizer Inc. (PFE) Selects Next Target in Antibody Discovery Collaboration



8/29/2012 9:50:44 AM

SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that Pfizer has selected a third target under its multi-year research and development collaboration with Theraclone. The collaboration, which began in January 2011, uses Theraclone’s I-STAR™ technology to discover monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. I-STAR™ technology is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES